Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Haemonetics (HAE) EBIAT (2016 - 2025)

Haemonetics (HAE) has 17 years of EBIAT data on record, last reported at $44.7 million in Q4 2025.

  • For Q4 2025, EBIAT rose 19.33% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $175.4 million, up 34.88%, while the annual FY2025 figure was $167.7 million, 42.64% up from the prior year.
  • EBIAT reached $44.7 million in Q4 2025 per HAE's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $58.0 million in Q1 2025 and bottomed at -$11.0 million in Q2 2021.
  • Average EBIAT over 5 years is $27.5 million, with a median of $32.1 million recorded in 2022.
  • Peak YoY movement for EBIAT: tumbled 162.65% in 2021, then skyrocketed 546.27% in 2022.
  • A 5-year view of EBIAT shows it stood at $14.9 million in 2021, then soared by 121.76% to $32.9 million in 2022, then dropped by 5.17% to $31.2 million in 2023, then grew by 20.02% to $37.5 million in 2024, then grew by 19.33% to $44.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $44.7 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.